GM12878 Cells
USD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The GM12878 cell line is a well-characterized human lymphoblastoid cell line, transformed with Epstein-Barr virus (EBV). It has been used as a standard Tier 1 cell line in the Encyclopedia of DNA Elements (ENCODE) project, making it one of the most widely studied models for genetic and transcriptomic research. Originating from a female donor, GM12878 is known for its stable karyotype compared to more commonly used cell lines such as HeLa and HEK293, which have extensive chromosomal aneuploidy. These cells are particularly valuable for understanding chromatin structure, gene regulation, and immune response due to their B-lymphocyte lineage. GM12878 cells have been employed in high-throughput studies, including ChIP-seq analyses to map transcription factor binding sites and histone modifications, MNase-seq for nucleosome mapping, and RNA-seq for transcriptome profiling. Studies involving GM12878 have elucidated aspects of transcription factor interactions, such as the binding of FOXM1 and its co-factors, and their roles in cell cycle and immune response pathways. Furthermore, GM12878 has served as a platform for genome editing experiments aimed at creating reference materials for next-generation sequencing (NGS) validation. For example, CRISPR/Cas9-mediated genome modifications have been introduced into GM12878 to develop control materials for cancer mutation analysis, illustrating its application in precision medicine and genetic testing. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Synonyms | GM-12878 |
Characteristics
| Age | Unspecified |
|---|---|
| Gender | Female |
| Morphology | Lymphoblast-like |
| Growth properties | Suspension |
Regulatory Data
| Citation | GM12878 (Cytion catalog number 305439) |
|---|---|
| Biosafety level | 2 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_7526 |
Biomolecular Data
| Viruses | Transformant: Epstein-Barr virus (EBV) |
|---|---|
| Mutational profile | Mutation: CYP2C19, p.Pro227Pro (c.681G>A) |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 15% FBS |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| Post-Thaw Recovery | After thawing, allow the cells to recover from the freezing process for at least 24 hours |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305439-260226 | Certificate of Analysis | 26. Mar. 2026 | 305439 |
| 305439-290425 | Certificate of Analysis | 18. Aug. 2025 | 305439 |